# Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

> **NCT01790516** · NA · TERMINATED · sponsor: **Georgetown University** · enrollment: 2 (actual)

## Conditions studied

- Head and Neck Squamous Cell Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** cetuximab
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT01790516
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-03
- **Final completion:** 2013-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low accruals--2 patients were enrolled in over a year
- **Last updated:** 2014-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01790516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01790516, "Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01790516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*